Healthcare Decliners: Sorrento Therapeutics (NASDAQ:SRNE), Fibrocell Science (NYSEMKT:FCSC), TG Therapeutics (NASDAQ:TGTX), CombiMatrix (NASDAQ:CBMX)

Sorrento Therapeutics Inc (NASDAQ:SRNE) announced in a press release that the National Institutes of Health (NIH) has provided funding for the development of bispecific antibodies. Two small business grants from the NIH will allow Sorrento to use its antibody conjugation technology platform to develop antibodies for two of the NIH’s anti-bacterial immunotherapies. Sorrento’s pipeline also shows promise in anti-infectives and auto-immune diseases. Sorrento Therapeutics Inc (NASDAQ:SRNE) stock performance was -6.70% in last session and finished the day at $5.85. Traded volume was 203,707.00million shares in the last session and the average volume of the stock remained 167.63K shares. The beta of the stock remained 4.23.

Fibrocell Science, Inc., (NYSEMKT:FCSC) on June 17, 2014 announced that it signed an Exclusive License Agreements with The Regents of the University of California. Fibrocell Science Inc (NYSEMKT:FCSC) dropped -7.25 percent to $3.20 Thursday on volume of 145,788.00million shares. The intra-day range of the stock was $3.10 to $3.52. Fibrocell Science Inc (NYSEMKT:FCSC) has a market capitalization of $130.74million.

Research analysts at MLV & Co raised their target price on shares of TG Therapeutics (NASDAQ:TGTX) from $10.00 to $16.00 in a report released on Wednesday. The firm currently has a “buy” rating on the stock. MLV & Co‘s price objective suggests a potential upside of 44.53% from the company’s current price. TG Therapeutics, Inc. (NASDAQ:TGTX)’s stock on July 10, 2014 reported a decrease of -6.21% to the closing price of $9.97. Its fifty two weeks range is $2.97 -$11.56. The total market capitalization recorded $408.22million. The overall volume in the last trading session was 304,242.00million shares. In its share capital, TGTX has 37.62million outstanding shares.

CombiMatrix Corp (NASDAQ:CBMX) on May 13 announced that Long Island Pathology (LI Path) is now offering its patients CombiMatrix’s chromosomal microarray analysis (CMA) testing for miscarriage analysis. LI Path, based in East Setauket, New York, is a physician-led diagnostic pathology laboratory serving the New York, New Jersey and northeastern Pennsylvania areas. On Thursday, shares of CombiMatrix Corp (NASDAQ:CBMX) dropped -7.94% to close the day at $2.32. Company return on investment (ROI) is -42.40% and its monthly performance is recorded as 7.41%. CombiMatrix Corp (NASDAQ:CBMX) quarterly revenue growth is -20.00%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone